89bio presents new analyses evaluating pegozafermin and potential benefit of non-invasive tests from the enliven phase 2b trial in mash patients at aasld the liver meeting® 2024

New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints new post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints
ETNB Ratings Summary
ETNB Quant Ranking